Clinical Trials | March 23, 2023
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Kyndryl's multi-cloud management solution leverages AI-based, cloud-hosted models to provide real-time metrics, events, logs, and traces
Cipla has received 8 inspectional observations in Form 483
The partnership is announced at Aero India 2023, Bangalore
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Subscribe To Our Newsletter & Stay Updated
